{"id":10367,"date":"2014-07-18T19:50:37","date_gmt":"2014-07-18T23:50:37","guid":{"rendered":"http:\/\/goldstocksforex.com\/?p=10367"},"modified":"2014-07-18T19:50:37","modified_gmt":"2014-07-18T23:50:37","slug":"to-sell-or-not-to-sell","status":"publish","type":"post","link":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/","title":{"rendered":"To sell or not to sell?"},"content":{"rendered":"<p>Recent acquisition Northern Star Resources [NST] in the <a href=\"http:\/\/researchandinvestment.com\/\" title=\"Research &amp; Investment: ASX 200 Prime Momentum\" target=\"_blank\">ASX 200 portfolio<\/a> is a great example of the conundrum faced by long-term investors when a new stock leaps out of the starting blocks. Profit-taking is evident from the tall shadows\/wicks early in the week and in the decline of 21-day Twiggs Money Flow. Medium-term selling pressure suggests the stock is likely to retrace and give back some of the gains of the last two weeks. The temptation must be great to sell the stock and lock in profits of close to 30 percent.<\/p>\n<p><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\"aligncenter\" width=\"525\" height=\"363\" title=\"NST\" alt=\"NST\" src=\"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2014\/2014-07-18-nst-ax.png?resize=525%2C363&#038;ssl=1\" \/><\/p>\n<p>It is important, however, to stick to the plan. We are investing for a longer time frame in anticipation of much larger gains. There is no guarantee that any individual stock, including NST, will deliver. But I can guarantee you that they will not deliver long-term gains if you sell within the first few weeks.<\/p>\n<p>Investors in S&amp;P 500 stock Micron Technology [MU] faced a similar conundrum in July 2013. The stock had put in a good run from $9.00 before encountering profit-taking as it approached $15.00. 21-Day Twiggs Money Flow retreated below zero and the stock fell back to $12.50. Many investors would have taken this as a sign to get out.<\/p>\n<p><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\"aligncenter\" width=\"525\" height=\"363\" title=\"MU July 2013\" alt=\"MU July 2013\" src=\"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2014\/2014-07-18-mu-us.png?resize=525%2C363&#038;ssl=1\" \/><\/p>\n<p>With hindsight, the decision to stay the course looks easy: support held at $12.50 and MU is now trading at $33.00. But I am sure that there were many investors who forgot their original plan and took profits at $12.50.<\/p>\n<p><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\"aligncenter\" width=\"525\" height=\"363\" title=\"MU 2013\/2014\" alt=\"MU 2013\/2014\" src=\"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2014\/2014-07-18-muw-us.png?resize=525%2C363&#038;ssl=1\" \/><\/p>\n<p> &#8230;.They just aren&#8217;t bragging about it.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recent acquisition Northern Star Resources [NST] in the ASX 200 portfolio is a great example of the conundrum faced by long-term investors when a new stock leaps out of the starting blocks. Profit-taking is evident from the tall shadows\/wicks early in the week and in the decline of 21-day Twiggs Money Flow. Medium-term selling pressure &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;To sell or not to sell?&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[37,54,56],"tags":[2299,2383,2501,2512,2791],"class_list":["post-10367","post","type-post","status-publish","format-standard","hentry","category-active-investing","category-momentum-trades","category-quantitative-investing","tag-micron-technology","tag-mu","tag-northern-star-resources","tag-nst","tag-profit-taking"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>To sell or not to sell? - the patient investor<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"To sell or not to sell? - the patient investor\" \/>\n<meta property=\"og:description\" content=\"Recent acquisition Northern Star Resources [NST] in the ASX 200 portfolio is a great example of the conundrum faced by long-term investors when a new stock leaps out of the starting blocks. Profit-taking is evident from the tall shadows\/wicks early in the week and in the decline of 21-day Twiggs Money Flow. Medium-term selling pressure &hellip; Continue reading &quot;To sell or not to sell?&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/\" \/>\n<meta property=\"og:site_name\" content=\"the patient investor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\" \/>\n<meta property=\"article:published_time\" content=\"2014-07-18T23:50:37+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/static.incrediblecharts.com\/images\/2014\/2014-07-18-nst-ax.png\" \/>\n<meta name=\"author\" content=\"ColinTwiggs\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ColinTwiggs\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/\"},\"author\":{\"name\":\"ColinTwiggs\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/cb072791ac83e8bae585007c133d54a5\"},\"headline\":\"To sell or not to sell?\",\"datePublished\":\"2014-07-18T23:50:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2014\\\/2014-07-18-nst-ax.png\",\"keywords\":[\"Micron Technology\",\"MU\",\"Northern Star Resources\",\"NST\",\"profit-taking\"],\"articleSection\":[\"Active Investing\",\"Momentum Trades\",\"Quantitative Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/\",\"name\":\"To sell or not to sell? - the patient investor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2014\\\/2014-07-18-nst-ax.png\",\"datePublished\":\"2014-07-18T23:50:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2014\\\/2014-07-18-nst-ax.png\",\"contentUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2014\\\/2014-07-18-nst-ax.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2014\\\/07\\\/18\\\/to-sell-or-not-to-sell\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/thepatientinvestor.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"To sell or not to sell?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"name\":\"The Patient Investor\",\"description\":\"Smart. Strategic. Unfiltered. \",\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/thepatientinvestor.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\",\"name\":\"The Patient Investor Pty Ltd\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"width\":250,\"height\":250,\"caption\":\"The Patient Investor Pty Ltd\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61572934660810\",\"https:\\\/\\\/www.instagram.com\\\/colin_thepatientinvestor\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/cb072791ac83e8bae585007c133d54a5\",\"name\":\"ColinTwiggs\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"caption\":\"ColinTwiggs\"},\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/author\\\/colin58s\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"To sell or not to sell? - the patient investor","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"To sell or not to sell? - the patient investor","og_description":"Recent acquisition Northern Star Resources [NST] in the ASX 200 portfolio is a great example of the conundrum faced by long-term investors when a new stock leaps out of the starting blocks. Profit-taking is evident from the tall shadows\/wicks early in the week and in the decline of 21-day Twiggs Money Flow. Medium-term selling pressure &hellip; Continue reading \"To sell or not to sell?\"","og_url":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/","og_site_name":"the patient investor","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61572934660810","article_published_time":"2014-07-18T23:50:37+00:00","og_image":[{"url":"http:\/\/static.incrediblecharts.com\/images\/2014\/2014-07-18-nst-ax.png","type":"","width":"","height":""}],"author":"ColinTwiggs","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ColinTwiggs","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/#article","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/"},"author":{"name":"ColinTwiggs","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5"},"headline":"To sell or not to sell?","datePublished":"2014-07-18T23:50:37+00:00","mainEntityOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"image":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incrediblecharts.com\/images\/2014\/2014-07-18-nst-ax.png","keywords":["Micron Technology","MU","Northern Star Resources","NST","profit-taking"],"articleSection":["Active Investing","Momentum Trades","Quantitative Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/","url":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/","name":"To sell or not to sell? - the patient investor","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/#primaryimage"},"image":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incrediblecharts.com\/images\/2014\/2014-07-18-nst-ax.png","datePublished":"2014-07-18T23:50:37+00:00","breadcrumb":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/#primaryimage","url":"https:\/\/www.incrediblecharts.com\/images\/2014\/2014-07-18-nst-ax.png","contentUrl":"https:\/\/www.incrediblecharts.com\/images\/2014\/2014-07-18-nst-ax.png"},{"@type":"BreadcrumbList","@id":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/18\/to-sell-or-not-to-sell\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thepatientinvestor.com\/"},{"@type":"ListItem","position":2,"name":"To sell or not to sell?"}]},{"@type":"WebSite","@id":"https:\/\/thepatientinvestor.com\/#website","url":"https:\/\/thepatientinvestor.com\/","name":"The Patient Investor","description":"Smart. Strategic. Unfiltered. ","publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thepatientinvestor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/thepatientinvestor.com\/#organization","name":"The Patient Investor Pty Ltd","url":"https:\/\/thepatientinvestor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","width":250,"height":250,"caption":"The Patient Investor Pty Ltd"},"image":{"@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61572934660810","https:\/\/www.instagram.com\/colin_thepatientinvestor"]},{"@type":"Person","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5","name":"ColinTwiggs","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","caption":"ColinTwiggs"},"url":"https:\/\/thepatientinvestor.com\/index.php\/author\/colin58s\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p9tQ4n-2Hd","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":13852,"url":"https:\/\/thepatientinvestor.com\/index.php\/2014\/07\/20\/to-sell-or-not-to-sell-2\/","url_meta":{"origin":10367,"position":0},"title":"To sell or not to sell?","author":"ColinTwiggs","date":"July 20, 2014","format":false,"excerpt":"Recent acquisition Northern Star Resources [NST] in the ASX 200 portfolio is a great example of the conundrum faced by long-term investors when a new stock leaps out of the starting blocks. Profit-taking is evident from the tall shadows\/wicks early in the week and in the decline of 21-day Twiggs\u2026","rel":"","context":"In &quot;Momentum Investing&quot;","block_context":{"text":"Momentum Investing","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investing\/momentum-investing-2\/"},"img":{"alt_text":"NST","src":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2014\/2014-07-18-nst-ax.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2014\/2014-07-18-nst-ax.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2014\/2014-07-18-nst-ax.png?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":16690,"url":"https:\/\/thepatientinvestor.com\/index.php\/2018\/07\/19\/time-to-sell-gold-stocks\/","url_meta":{"origin":10367,"position":1},"title":"Time to sell Gold stocks","author":"Colin Twiggs","date":"July 19, 2018","format":false,"excerpt":"Stocks: Evolution Mining, Northern Star Resources, Regis Resources, St Barbara Symbols: EVN, NST, RRL, SBM Exchange: ASX Date: July 19, 2018 The Dollar price of gold has broken support at $1240\/ounce, signaling a primary down-trend. The Dollar Index continues to test resistance, consolidating in a narrow band below 95, a\u2026","rel":"","context":"In &quot;Australia &amp; NZ&quot;","block_context":{"text":"Australia &amp; NZ","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/countries-regions\/australia-nz-countries-regions\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":36793,"url":"https:\/\/thepatientinvestor.com\/index.php\/2022\/08\/29\/northern-star-nst\/","url_meta":{"origin":10367,"position":2},"title":"Northern Star (NST)","author":"Colin Twiggs","date":"August 29, 2022","format":false,"excerpt":"We reduced our fair value estimate for Northern Star (NST) by 1%, to A$9.33 per share, based on the following projections: production of 1.55Moz in FY23; average gold price of A$2600 per ounce and all-in sustaining cost (AISC) of A$1660 per ounce; and an effective tax rate of 30%. We\u2026","rel":"","context":"In &quot;Australian Growth&quot;","block_context":{"text":"Australian Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/asx-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":21974,"url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/10\/12\/gold-proposed-northern-star-nst-and-saracen-sar-merger\/","url_meta":{"origin":10367,"position":3},"title":"Proposed Northern Star (NST) and Saracen (SAR) merger","author":"Colin Twiggs","date":"October 12, 2020","format":false,"excerpt":"The proposed merger between Northern Star (NST) and Saracen (SAR) would bring together two strong teams and consolidate existing Australian operations around Kalgoorlie and Yandal under the control of a single entity. Synergies anticipated by management are between $1.5bn and $2.0bn (AUD) over the next 10 years (pre-tax). Merger Proposal\u2026","rel":"","context":"In &quot;Australian Growth&quot;","block_context":{"text":"Australian Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/asx-growth\/"},"img":{"alt_text":"NST-SAR Operations","src":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2020\/10\/2020-10-12-nst-sar-ops.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2020\/10\/2020-10-12-nst-sar-ops.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2020\/10\/2020-10-12-nst-sar-ops.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2020\/10\/2020-10-12-nst-sar-ops.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":24515,"url":"https:\/\/thepatientinvestor.com\/index.php\/2021\/03\/12\/australian-growth-performance-at-28-february-2021\/","url_meta":{"origin":10367,"position":4},"title":"Australian Growth: Performance at 28 February 2021","author":"Andy","date":"March 12, 2021","format":false,"excerpt":"Australian Growth portfolio performance since inception on 1 July 2018 is set out below. We expect to hold most growth stocks for 5 to 10 years. Individual Stocks Notes: Performance is calculated in Australian Dollars. Annualized performance is calculated using the CAGR formula. Returns are calculated after brokerage costs but\u2026","rel":"","context":"In &quot;Australian Growth Performance&quot;","block_context":{"text":"Australian Growth Performance","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/australian-growth-performance\/"},"img":{"alt_text":"Australian Growth Annualized Performance 1-Jul-2018 to 28-Feb-2021: Portfolio 4.49%, ASX 200 Accumulation Index 6.73%","src":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2021\/03\/perf-2021-02-aus.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2021\/03\/perf-2021-02-aus.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2021\/03\/perf-2021-02-aus.png?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":20357,"url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/04\/23\/australian-gold-miners-update\/","url_meta":{"origin":10367,"position":5},"title":"Australian Gold Miners update","author":"Colin Twiggs","date":"April 23, 2020","format":false,"excerpt":"At present we hold three gold mining stocks and have revised our suggested price limits, as price trends upwards, with the intention of buying on the dips: Evolution Mining (EVN) - $4.65 Northern Star (NST) - $12.50 Saracen Mineral Holdings (SAR) - $4.25 Evolution Mining (EVN) Evolution (EVN) respected secondary\u2026","rel":"","context":"In &quot;Australian Growth&quot;","block_context":{"text":"Australian Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/asx-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/10367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/comments?post=10367"}],"version-history":[{"count":0,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/10367\/revisions"}],"wp:attachment":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/media?parent=10367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/categories?post=10367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/tags?post=10367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}